| Name | Title | Contact Details |
|---|
VisionQuest Biomedical Inc. is a research and development company founded in 2007 with the objective of bringing affordable medical devices to the ophthalmic and diabetes care markets. VisionQuest has developed multiple medical devices with funding from the National Institutes of Health and is now looking to transfer those technologies to the commercial space. Our devices are currently being used in the United States and Latin America.
Henry Schein, Inc. is the world`s largest provider of health care products and services to office-based dental, animal health and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the S&P 500® and NASDAQ 100® Indexes, Henry Schein employs more than 21,000 Team Schein Members and serves more than one million customers. The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services. Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 32 countries. The Company`s sales reached a record $11.6 billion in 2016, and have grown at a compound annual rate of approximately 15 percent since Henry Schein became a public company in 1995
Founded in 1985, Axelgaard Manufacturing Co., Ltd. (AMC) has grown to become the premier manufacturer of neurostimulation electrodes. Our primary brand is our patented PALS Neurostimulation Electrodes. We are dedicated to providing the highest quality
Advanced Cardiac Therapeutics, Inc. is a pre-commercial, medical device company that designs and manufactures a catheter-based system for the treatment of patients with AFIB. AFIB is characterized by an irregular, often rapid heart rate that commonly causes poor systemic blood flow. The Company`s mission is to dramatically improve the treatment of AFIB through the introduction of products based on its proprietary catheter and generator system. ACT`s technology is the only system in the world to leverage feedback from four unique capabilities: temperature sensing, low irrigation flow rates, high resolution EGM attenuation and contact sensing. The ACT system is not currently approved for commercial use.
To improve the lives of those impacted by disease and disability. To provide accessible, accurate, and reliable analysis in a way that facilitates and adapts to our clients` needs to progress their clinical trials at the fastest possible pace. While our technology makes us unique, it is our people who make us special. Our teams utilize creativity, flexibility and expertise to design personalized solutions to meet our customers` goals and objectives. But what truly sets us apart is the internal motivation of our employees and the pride they take in helping customers affect the lives of those in need.